Abstract: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell.

Abstract: The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying out the processes and to the cell preparations prepared by the processes.

Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.

Abstract: The present invention relates to a method for treating an autoimmune disease, such ulcerative coliteis or crohns disease characterized by lymphocyte accumulation at epithelial sites. The method involves administering to a subject an effective amount of an antibody that selectively binds to an &agr;E&bgr;7 integrin or an &agr;E subunit thereof.

Abstract: This invention provides a method of inhibiting an allergic response in a subject by inhibiting T cell activation of B cells, wherein said method comprises administering to the subject an antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5C8 produced by the hybridoma having ATCC Accession No. HB 10916.

Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.

Abstract: The present invention relates to a method of inhibiting HIV infection of cells susceptible to HIV infection. The method comprises contacting such cells with an agent (such as an anti-CD44 antibody) that inhibits CD44-facilitated HIV infection of the cells.

Abstract: Methods to treat spinal cord injury using &agr;d monoclonal antibodies are disclosed.

Abstract: This invention concerns interactions among APRIL/G70, AGP-3/BLYS, BCMA, and TACI and related methods of use and compositions of matter. It has been found that (1) sAPRIL/G70 binds to the cell-surface receptors BCMA and TACI on T and B lymphoma cells, resulting in stimulation of proliferation of primary human and mouse B and T cells both in vitro and in vivo; (2) APRIL competes with AGP3's binding to TACI and BCMA; (3) sBCMA inhibits APRIL and AGP3 binding to its receptors; (4) sBCMA ameliorates T cell dependent and T cell independent humoral immune responses in vivo; (5) sTACI inhibits APRIL and AGP3 binding to its receptors and ameliorates T cell dependent and T cell independent humoral immune responses in vivo; and (6) BCMA exhibits similarity with TACI within a single cysteine rich domain located N-terminal to a potential transmembrane domain. These discoveries provides a strategy for development of therapeutics for treatment of autoimmune diseases, and cancer, for prevention of transplant rejection.

Abstract: A method for the treatment of T cell mediated disorders is described. The method involves administering to a subject a therapeutically effective amount of an anti-human CD40 antibody. Disease states suitable for treatment with this method include graft versus host disease and transplant rejection and auto immune disease such as type I diabetes, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myesthenia gravis.

Abstract: This invention provides for a method for inhibiting rejection of a transplant organ in a subject which comprises administering to the subject an antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. The present invention further provides for a method for inhibiting rejection of a transplant organ in a subject, which comprises administering to the subject a pharmaceutical composition comprising a monoclonal antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. In one embodiment of the invention, the transplant organ is a heart, a kidney or a liver. In another embodiment, the monoclonal antibody is 5c8 produced by the hybridoma having ATCC Accession No. HB 10916.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.

Abstract: Monoclonal antibodies which specifically bind to human interleukin-5 (IL-5) are described for treatment of IL-5-mediated inflammatory conditions. Fragments or chimeric binding molecules derived from these monoclonal antibodies are also described for use.

Abstract: The present invention relates to a novel composition for identifying and suppressing the growth of tumor cells, which comprises antibodies which react with proteins having N-glycosidically bonded saccharides.

Abstract: This invention is based on the discovery that an essentially nonallergenic covalent conjugate of a model allergen, ovalbumin (OA), and monomethoxypolyethylenc glycol (mPEG) is capable of inactivating in vivo and ex vivo granulocytes sensitized with anti-OA IgE antibodies (Abs). As a result of the inactivation of the granulocytes, subsequent challenge with OA was not followed by degranulation and the consequent release of the mediators of anaphylaxis (vasoactive compounds) from the granules of these cells. These results, therefore, provide a basis for the treatment of symptoms of an already established immune response against an allergen or allergens.

Abstract: Novel monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they may be converted to chimeric or humanized forms, immunoconjugates or antibody fragments (generally described as binding molecules). The products are useful for the prophylaxis or treatment of transplant rejection, paticularly in combination with other antibodies to activated T-cells, for example CD7 antibodies.

Abstract: A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens.

Abstract: Disclosed are methods and compositions for use in immunotherapy. These methods and compositions are particularly useful for exploiting dendritic cells to present an antigen to a patient, particularly where the patient has a disease associated with the antigen. The invention provides methods for treating a patient having a disease associated with an antigen. The methods according to the invention comprise combining ex vivo an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen, wherein the patient receives a therapeutic benefit.

Abstract: The current therapeutic approach to treating patients with HIV-1 infection involves the use of one or more highly active antiretroviral therapeutics (HAART). While efficacious, this approach does not address the existance of latently infected cells. Such latently infected cells can be reactivated, resulting in the expression of infectious virus and reinitiation of the disease process. The present invention relates to a novel and highly efficacious approach to eradication of HIV-1. Patients that are treated with HAART are then treated with an intensification regimen wherein hydroxyurea and didanosine (ddI) are given to inhibit any residual viral replication. The therapeutic regimen is continued with the addition of compounds, such as OKT3 and IL-2, that activate latently infected cells, thereby stimulating the replication of any proviruses. These re-activated viruses are subsequently inhibited by the HAART and hydroxyurea/ddI therapeutics.

Abstract: This invention relates to an antibody which is a modified version of a therapeutic antibody with affinity for a cell-surface antigen, said antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.

Abstract: A novel human serrate-2 polypeptide consisting of a polypeptide containing the amino acid sequence described in SEQ ID NO:1 in the Sequence Listing and having the effect of regulating the differentiation of undifferentiated cells involving stem cells; its gene; a process for producing the same; and an antibody specifically recognizing the polypeptide.

Abstract: Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.

Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.

Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.

Abstract: A method for treating autoimmune diseases comprising administering to a patient in need of such treatment a therapeutically effective amount of an immunotoxin comprising an anti-human CD86 monoclonal antibody IG10H6D10 as deposited in the ECACC collection under No. 95060210 or a humanized antibody, a single-chain antibody or fragments and specificity of said monoclonal antibody, coupled to a toxin or active fragments thereof wherein the binding of the immunotoxin to CD86 results in the killing of the CD86 expressing cell.

Abstract: Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.

Abstract: Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Reperfusion injury, in an non-transplant recipient, is a condition associated with CD40 ligand-induced activation of CD40-bearing cells. Therefore, reperfusion injury can be treated by the administration of anti-human CD40L monoclonal antibodies, such as those described herein (e.g. 5c8 mAb).

Abstract: Method for the treatment of multiple sclerosis and other T cell mediated autoimmune disorders is described. The method involves administering to a subject a therapeutically effective amount of an antagonist of a receptor on a surface of a T cell which mediates contact dependent helper effector functions, for example, an anti-gp39 antibody.

Abstract: According to the invention, there is provided a human or animal cell expressing an antibody directed against a surface antigen on an antigen-presenting cell (APC) and lacking parental tumor-derived immunoglobulin.

Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.

Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract: A method of treating graft-vs-host diseases by administration of bone marrow and an anti-gp39 antibody specific to human gp39 is provided.

Abstract: The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells.

Abstract: The present invention relates to a method for adjusting the affuinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

Abstract: The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.

Abstract: It is the objective and purpose of the present invention to provide a monoclonal antibody having the property of causing apoptosis on myeloid cells. This invention relates to a monoclonal antibody having the property of causing apoptosis on myeloid cells, and fragments thereof, and furthermore relates to a hybridoma producing the monoclonal antibody. Since the monoclonal antibodies of the present invention are useful as antibodies recognizing and identifying antigens causing apoptosis on myeloid cells specifically and besides have the property of causing apoptosis on myeloid cells, they may be used as medicine useful in the field of remedies for myelocytic leukemia utilizing the property.

Abstract: A method of suppressing tumor cell growth, comprising administering to a mammal in need thereof an amount of an inhibitor of eosinophilia sufficient to result in suppression of tumor cell growth is disclosed.

Abstract: A therapeutic agent for rheumatoid arthritis comprising anti-IL-8 antibody as an active ingredient.

Abstract: Methods for treating and inhibiting disease and symptoms associated with the human immunodeficiency virus (HIV) are provided. The method includes transforming the human immunodeficiency virus (HIV) infection into a nonserious disease through the infusion of monoclonal antibodies directed against particular antigens on anti-self, anti-CD4 cytotoxic T-lymphocytes. The monoclonal antibodies are primarily directed against the alpha or beta chain of LFA-1.

Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.

Abstract:

Abstract: A method for treating a pro-tumor immune response in an individual having, or suspected of having, a pro-tumor immune response, by administering a therapeutically effective amount of an immunotherapeutic composition which binds to a determinant on B cells, resulting in B cell depletion including of B cells that may be involved in promotion of tumor progression. Also provided are immunotherapeutic compositions which can be used for treating a pro-tumor immune response.

Abstract: The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

Abstract: Mean survival times of a functional transplant of solid organs in a patient are increased by administering to the patient an initial dosing of a therapeutically effective amounts of a monoclonal antibody directed against the human LFA-1 molecule in the two hours after grafting and then administering daily dosing during a period of approximately nine days.

Abstract: Humanized immunoglobulins specifically reactive with L-selectin are prepared employing recombinant DNA technology for use in e.g., treatment of inflammatory disorders.

Abstract: This invention provides monoclonal antibodies that bind to both E-selectin and to P-selectin, and inhibit the binding of these proteins to counterreceptors. The invention also provides nucleic acids encoding these antibodies and methods for using the antibodies in the treatment of inflammatory conditions.

Abstract: The present invention relates to methods and products for immunotherapy resulting in the stimulation of T-cell proliferation. The products of the invention are peptides that bind to CTLA-4 and co-stimulate the proliferation of T-cells by inhibiting the binding of B7 to CTLA-4. Pharmaceutical compositions including such peptides are also provided. The invention further provides in vitro and in vivo therapeutic methods employing the peptides of the invention.

Abstract: Disclosed is a method for treating tissue necrosis (loss) in an animal. Tissue necrosis is treated by providing the subject with an anti-adhesion cell agent capable of binding an ICAM-1 antigen, a CD18 antigen, an L-selectin agent, a CD44 antigen, a P-selectin antigen, a VCAM-1 antigen, an ICAM-2 antigen, or a fragment thereof. Also provided is a method for preventing thermal-related tissue loss or necrosis, particularly the thermal injury and progressive tissue necrosis which results from a burn injury. Thermal-related tissue injury surrounding a thermal injury site is inhibited or prevented by providing an animal with an anti-adhesion agent, such as an anti-CD18 antibody, an anti-ICAM-1 antibody, or a mixture or fragment thereof. A method for inhibiting/preventing scarring attendant healing of a thermal injury is also disclosed.

Abstract: Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.